JW Pharmaceutical announced on Friday that it received approval from the Food and Drug Administration (FDA) for the clinical trial plan (IND) of its hair loss treatment candidate, JW0061.
Following this approval, JW Pharmaceutical will launch Phase 1 clinical research on JW0061 at Seoul National University Hospital, involving 104 healthy adult participants, both Korean and Caucasian.
The clinical trial aims to assess the safety and tolerability of JW0061 when applied directly to the scalp and to evaluate its pharmacokinetic properties, including absorption and metabolism.
JW0061 is an innovative drug candidate that directly binds to the GFRA1 receptor of hair follicle stem cells to stimulate hair growth.
Unlike existing treatments that rely on male hormone suppression or vasodilation, this new formulation activates the hair growth pathway physiologically, making it suitable for both men and women as a topical treatment.
This compound has demonstrated its potential through impressive preclinical data presented at several international conferences.
In human skin organoid models, it showed a hair follicle generation effect 7.2 times greater than standard treatments. Animal model tests also confirmed a 39% improvement in hair growth, highlighting its potential as a groundbreaking global drug.
JW Pharmaceutical has secured patent registrations for JW0061 in various countries, including South Korea, Japan, China, Australia, and Brazil. Last month, the company obtained a U.S. patent for JW0061, granting it exclusive rights to its core technology in the U.S. market until 2039.
Based on the Phase 1 results, JW Pharmaceutical plans to refine its subsequent clinical development plans and systematically review indications and development strategies.
A spokesperson for JW Pharmaceutical said that the IND approval is a major milestone as JW0061 moves from preclinical achievements to the clinical stage. The spokesperson added that the company is committed to advancing clinical development without delays to establish JW0061 as a pioneering global hair-loss treatment.